Lonza Capabilities Update August 2026: Cell Line Development

Omeco Barrett, Principal Scientist in Lonza's Global Process Development group, will highlight the company's latest advances in cell line expression technology and cell line development (CLD). Drawing on Lonza's deep expertise in mammalian expression systems, this discussion explores how recent innovations are helping developers move molecules from concept to clinic faster and with greater confidence.

A central focus will be the newly launched GS Ori-Go™ vector technology, which delivers outstanding titers and robust expression stability across Lonza's mammalian platform. Beyond its performance benefits, GS Ori-Go™ opens the door to streamlined, more efficient CLD workflows—reducing complexity at critical development stages and accelerating DNA-to-IND timelines to as little as six months. Together, these capabilities offer a compelling path to shortening development timelines without compromising the quality, consistency, or manufacturability that biologics programs demand.